Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

NCT04293679 · View on ClinicalTrials.gov ↗

Study Summary

This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as Intralesional injection in subjects with isSCC. Goals: * To determine the safe and effective recommended dose of STP705 for the treatment of isSCC. * Analysis of biomarkers common to isSCC formation pathway including TGF-β1 and COX-2.

Interventions

  • DRUG STP705

Study Locations (1)

Florida

  • Center for Clinical and Cosmetic Research — Aventura

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2019-03-21
Est. Completion 2020-10-21
Phase Phase 1

Sponsor

Sirnaomics

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04293679

The ClinicalTrials.gov registry entry for NCT04293679 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirnaomics, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Bowen's Disease appearing as the primary indexed condition, and to 1 intervention — of which STP705 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04293679 reports 1 study location spanning 1 distinct geographic area — top geographies include Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04293679 about?

NCT04293679 is a clinical study titled "Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC". This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various d...

What is the current status of trial NCT04293679?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-03-21. Estimated completion is 2020-10-21.

What conditions does trial NCT04293679 study?

This clinical trial studies the following conditions: Bowen's Disease, Cutaneous Squamous Cell Carcinoma in Situ. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04293679?

The interventions under investigation include: STP705 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04293679?

This trial is sponsored by Sirnaomics, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04293679 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial